TAG and Allies Rally for Affordable HIV Prevention Medication
Statement / Press • 2019On Monday February 18, TAG, some of our allies, and a number of elected officials attended a rally in New York City calling on the National Institutes of Health to exercise its march-in rights and break Gildead’s patent on Truvada.
Public Comment on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions
Letters • 2019TAG recently submitted this public comment on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions, highlighting the need to mitigate national supply challenges and shortages of critical TB drugs.
TAG Welcomes HHS Lawsuit Against Gilead; Urges Dramatic Scale-Up of Low-Cost PrEP
Statement / Press • 2019Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.
Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson
Statement / Press • 2019Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.
TAG Submitted Testimony to the House Committee on Oversight and Reform Hearing on “HIV Prevention Drug: Billions in Corporate Profits After Millions in Taxpayer Investments”
Letters • 2019TAG submitted testimony for the record for the hearing, "HIV Prevention Drug: Billions in Corporate Profits after Millions in Taxpayer Investments" at the request of members of the House Oversight and Reform Committee.
Statement from Treatment Action Group on FDA Priority Review of TB Alliance’s New Anti-TB Drug Pretomanid
Statement / Press • 2019Treatment Action Group (TAG) welcomes the exciting news of a novel tuberculosis (TB) drug entering priority review by the Food and Drug Administration (FDA). Pretomanid represents only the fourth new TB drug to go through stringent regulatory review in the past half a century, and the first developed by a not-for-profit organization.
Treatment Action Group Applauds U.S. Preventive Services Task Force “A” Ratings for Pre-Exposure Prophylaxis and HIV Screening
Statement / Press • 2019TAG recently released this statement strongly supporting the final “A” ratings issued by the U.S. Preventive Services Task Force regarding PrEP for individuals highly vulnerable to infection and HIV screening for all Americans between the ages of 15 and 65, including pregnant women.
Public Comment on USPSTF Draft Recommendations for PrEP and HIV Screening
Letters • 2019The US Preventive Services Task Force (USPSTF) recently released draft recommendations regarding HIV screening for all Americans ages 15-65, including pregnant women, and pre-exposure prophylaxis (PrEP) for individuals highly vulnerable to HIV infection.
Getting Rid of the Boogeyman: The Reality of Prescription Drug Price Controls
TAGline • 2018By Annette Gaudino, HCV/HIV Project Co-Director, TAG Do you remember how old you were when you stopped believing in the monster under your bed? How many times did you have to look and see nothing there before you finally believed the danger wasn’t real? In the United States, the fear that price controls would irrevocably…
TAG Welcomes Price Reductions for TB Medicines
Statement / Press • 2018Countries and donors must do more to ensure all people with TB have access; further price reductions for newer medicines required.